Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

IT stocks boost the markets
Tue, 20 Sep 09:30 am

Asian stock markets have opened the day on a mixed note. Stock markets in Honk Kong (down 0.1%), Indonesia (down 1.3%) and Japan (down 1.4%) are in the red while China (up 0.4%) and Singapore (up 0.1%) are in the green. The Indian stock markets have opened the day on a firm note. Stocks in the Consumer Durables and Information Technology (IT) space are leading the gains while stocks in Oil & Gas are trading in the red.

The BSE-Sensex is trading higher by 100 points (0.6%) and the NSE-Nifty is higher by around 33 points (0.6%). Mid cap and small cap stocks are trading in the green, with the BSE Mid Cap and BSE Small Cap indices up by 0.4% and 0.3% respectively. The rupee is trading at 48.1 to the US dollar.

Pharma Stocks have opened the day in the green with Ranbaxy and Cipla in the green. Sun Pharma has announced that the regulatory issues with the US Food and Drug Administration (USFDA) on its Cranbury plant have been resolved completely. However, things are not all hunky dory for the company. Sun Pharma has also lost a patent dispute with French drug-maker Sanofi. The dispute was over a patent on colon cancer drug - Eloxatin. The US District Court of New Jersey has ruled against Sun pharma over the resolution of the Eloxatin (oxaliplatin) patent litigation. This will ensure the drugs exclusivity for the US market till August 2012. Eloxatin sales are estimated to be at US$ 350 m for one quarter.

Auto stocks have opened the day on a firm note with Tata Motors and Bajaj Auto in the green. Tata Motor's Jaguar Land Rover (JLR) has announced that it will invest about GBP 355 m (approximately Rs 26.6 bn) on a new engine plant in central England. The UK government, which was keen to support manufacturing in Britain, has promised to provide up to GBP 10 m (approximately Rs 750 m). The plant is expected to create about 750 direct jobs while also supporting several thousand jobs across the UK economy. The luxury carmaker already employs more than 19,000 people in Britain and supports up to 140,000 jobs. Robust demand for JLR cars from emerging economies such as China and Russia has given it a significant boost. According to JLR CEO Ralf Speth, the company will invest about GBP 1.5 bn (approximately Rs 112.5 bn) a year for the next five years on new product developments. As such, expanding the engine range would aid the company to harness the full global potential of the Jaguar and Land Rover brands.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT stocks boost the markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.